logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > LAM-561 in addition to radiation therapy and temozolomide for glioblastoma –adjuvant

< Back

LAM-561 in addition to radiation therapy and temozolomide for glioblastoma –adjuvant

Drugs

Cancer and Palliative Care

May 2021


LAM-561 in addition to radiation therapy and temozolomide is in development as a treatment option for newly diagnosed glioblastoma patients. Glioblastoma is a fastgrowing brain tumour that develops from glial cells in the brain, is an aggressive brain cancer that typically results in death within months following diagnosis if not treated. Brain cancers are the ninth most common cancers in the UK; gliomas, of which glioblastoma is a type of, contribute to about one third of brain tumours. Current therapies remain palliative and include surgery to remove as much of the tumour as possible, followed by chemotherapy and/or radiation therapy. Glioblastoma represents a highly unmet medical need due to its dismal prognosis, meaningful disability and lack of new agents. LAM-561 is in development as a new oral treatment for newly diagnosed glioblastoma. It mimics the structure of oleic acid, a fatty acid, and can cross the blood brain barrier to influence the environment within brain cells; importantly, LAM-561 does not affect healthy cells and only targets tumour cells. If licensed, LAM-561 would provide an additional treatment options for patients diagnosed with glioblastoma.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts